Delgocitinib - Japan Tobacco

Drug Profile

Delgocitinib - Japan Tobacco

Alternative Names: JTE-052; JTE-052A

Latest Information Update: 16 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Japan Tobacco
  • Class Antiallergics; Pyrimidines
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Autoimmune disorders; Hypersensitivity; Inflammation

Most Recent Events

  • 15 Jan 2018 Japan Tobacco and Torii announce intention to submit MAA for JTE 052 ointment in Atopic dermatitis in Japan in 2018
  • 15 Jan 2018 Efficacy data from a phase III trial in Atopic dermatitis released by Japan Tobacco
  • 31 May 2017 Japan Tobacco initiates enrolment in a phase III trial for Atopic dermatitis in Japan before May 2017 (JapicCTI-173554)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top